Journal of International Oncology››2013,Vol. 40››Issue (2): 137-140.
Previous ArticlesNext Articles
SUN Li, LI Gong, ZHAO Ying, XU Cen-Cen
Second Department Of Oncology,Chinese People's Armed Police General Hospital,Beijing 100039,China
Online:
2013-02-08Published:
2013-01-25Contact:
Corresponding author: LI Gong, E-mail: dr_gongli@163.com E-mail:dr_gongli@163.comSUN Li, LI Gong, ZHAO Ying, XU Cen-Cen. Application of PET-CT in liver cancer[J]. Journal of International Oncology, 2013, 40(2): 137-140.
[1] | Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325. |
[2] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[3] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[4] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[5] | Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p, H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349. |
[6] | Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358. |
[7] | Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363. |
[8] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[9] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[10] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[11] | Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291. |
[12] | Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng.Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor[J]. Journal of International Oncology, 2024, 51(5): 298-302. |
[13] | Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311. |
[14] | Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(4): 210-216. |
[15] | Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||